AptarGroup (ATR) Lifts Its Dividend Following Earnings, Is It Still 11% Below Fair Value?
AptarGroup, Inc. Reports Third Quarter 2026 Results and $58.0 million Loss on Russia Deconsolidation
Investing in AptarGroup (ATR)? Don't Miss Assessing Its International Revenue Trends
Aptar: 3 Key Takeaways for Long-Term Investors
AptarGroup, Inc. (ATR) Q3 2026 Earnings Call Transcript
What AptarGroup (ATR) Said on Its Q3 Earnings Call
AptarGroup Q3 2026 Earnings Call Transcript
AptarGroup, Inc. 2026 Q3 - Results - Earnings Call Presentation
AptarGroup (NYSE:ATR) Q3 2026: Revenue and EPS Beat, But Margin Pressure and Russia Charge Weigh on Reaction
AptarGroup (ATR) Q3 Earnings and Revenues Beat Estimates
AptarGroup: Q3 Earnings Snapshot
Aptar Reports Third Quarter 2026 Results
Aptar Increases Quarterly Dividend to $0.50 Per Share
AptarGroup Raises Quarterly Cash Dividend From $0.48 To $0.50 Per Share
AptarGroup Sees Q4 Adj EPS $1.39-$1.47 vs $1.41 Est
Aptar Pharma and Stevanato Group Collaborate to Help Accelerate Pre-Filled Syringe System Selection
AptarGroup's Pharma Unit Partners With Stevanato Group To Provide System-Level Data Supporting Earlier Evaluation Of Pre-Filled Syringe Configurations
AptarGroup To Acquire PULMOTREE, A Munich, Germany-based Life Science Company Specializing In Pulmonary Drug Delivery Systems For Targeted Delivery To The Lungs; Terms Not Disclosed
Earnings Preview: AptarGroup (ATR) Q3 Earnings Expected to Decline
Aptar Announces CE Marking for LuerVax® and Accompanying Spray Divider, Strengthening Support for Vaccine Developers
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.